CURRENT PRACTICE IN ANTIMALARIAL DRUG PRESCRIBING IN RHEUMATOID-ARTHRITIS
- 1 June 1986
- journal article
- research article
- Vol. 13 (3) , 551-555
Abstract
An analytic mail survey was conducted among Canadian and Australian rheumatologists to probe current prescribing practices for antimalarial agents. Ninety-six percent of respondents prescribed antimalarial therapy for rheumatoid arthritis with a preference for the use of hydroxychloroquine. The most frequently reported risk estimates for serious retinal toxicity were 0.01 and .ltoreq. 0.001. Seventy-eight percent of rheumatologists reported 1 to 50% of patients refusing antimalarial therapy, usually because of concern regarding ocular toxicity. Our study indicates the importance of presenting the relevant risk:benefit data in an accurate and comprehensible form to potential recipients.This publication has 6 references indexed in Scilit:
- COMPARISON OF HYDROXYCHLOROQUINE AND CHLOROQUINE USE AND THE DEVELOPMENT OF RETINAL TOXICITY1985
- Controlled trial of hydroxychloroquine and d‐penicillamine singly and in combination in the treatment of rheumatoid arthritisArthritis & Rheumatism, 1984
- ANALYSIS OF TREATMENT TERMINATIONS WITH GOLD AND ANTI-MALARIAL COMPOUNDS IN RHEUMATOID-ARTHRITIS1980
- Ophthalmologic safety of long‐term hydroxychloroquine treatmentArthritis & Rheumatism, 1979
- IS CHLOROQUINE OBSOLETE IN TREATMENT OF RHEUMATIC DISEASE?The Lancet, 1979
- Ocular Lesions in Rheumatoid Arthritis and Related Disorders with Particular Reference to RetinopathyNew England Journal of Medicine, 1965